by MASC-Admin | Jul 11, 2018 | Current News
Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic MCC progressed on chemotherapy;Paul Nghiem et al. At the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr Suzanne Topalian (John...
by MASC-Admin | Jul 11, 2018 | Current News
Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic MCC progressed on chemotherapy;Paul Nghiem et al. At the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr Paul Nghiem (University...
by MASC-Admin | Jul 11, 2018 | Current News
Durable tumor regression and OS in patients with advanced MCC receiving pembrolizumab as first-line therapy;Paul Nghiem et al. At the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr Paul Nghiem (University of Washington) presented data on patients...
by MASC-Admin | Apr 4, 2018 | Current News
“On Friday 1st June 2018, Merck/Pfizer announced that the current BAVENCIO (avelumab) metastatic Merkel cell carcinoma access program in Australia will be closed. Any patient request already approved on the access program was grandfathered on Friday, 1st June, and...
Recent Comments